HLX79 (E-602) Plus Rituximab Produces Fast and Durable Responses in Patients with Membranous Nephropathy (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-OR102; Pres time: Oct 23, 2026; 11:00 AM - 11:15 AM; Location: Bluebird Ballroom, Convention Center; P2 | "Methods This Phase 2 double-blinded RCT (NCT07038382) randomized 26 MN patients 3:1 (HLX79 + HLX01 [Rituximab (RTX) biosimilar] vs HLX01 alone) across three HLX79 dose cohorts (10, 20, 30 mg/kg). These findings support advancement of this novel, first-in-class molecule. Efficacy"
Clinical • Fibrosis • Glomerulonephritis • Immunology • Renal Disease • CD163
|
|
Zhilian Li; Xueqing Yu; Qiuling Fan; Li Zuo; Deguang Wang; Rong Lv; Junxia Wang; Zhiming Ye; Hui Xu; Leping Shao Shao; Yan Yan; Huijuan Mao; Aimin Zhong; Cheng Chen; Wanhong Lu; Lizhi Cao; Louis Brenner; Li Peng; James W. Broderick; Yunna Zang; Yating Wang; Lin Han; Brad Rovin
|